Dr. Timothy T. Stenzel
Chief Operating Officer
chemistry
invivoscribe
Malaysia
Biography
Dr. Stenzel, COO of Invivoscribe since 2014, brings an extensive background in executive leadership, innovation, companion diagnostics, research and development, FDA regulations, clinical laboratory operations as well as commercial and other operational organizations. He has played important roles in the development and launch of more than 30 IVD products. His experience includes serving as Chief Scientific Officer and founder of the Molecular Diagnostics franchise at Quidel, Chief Medical Officer and Vice President of Research and Development at Asuragen. Prior to Asuragen, Dr. Stenzel was a senior leader at Abbott Laboratories where he was Senior Director for Medical, Regulatory and Clinical Affairs at Abbott Molecular. Prior to Abbott, he was Assistant Professor of Pathology at Duke University. His research focused on various cancers and the genetics of inherited diseases, where he directed the Clinical Cytogenetic and Molecular Diagnostics Laboratories, and where he taught numerous courses in the School of Medicine.
Research Interest
...
